Method for detecting extracranial metastases in metastatic brain injury patients |
||||||||||||||||||||||||||
|
IPC classes for russian patent Method for detecting extracranial metastases in metastatic brain injury patients (RU 2300110):
Method for predicting cerebral metastasis lesion foci in metastatic brain injury patients / 2300109
Method involves determining thyroxin hormone concentration in cerebral metastasis-ill patient blood prior to treatment beginning. Its concentration being found within the limits of 68.0-115.0 nmole/l, 1 to 3 metastatic lesion foci are predicted to be available. The concentration being from 38.0 to 50.0 nmole/l, more than 4 p metastatic lesion foci are predicted to be available.
Method for predicting extracranial metastases development in patients having metastases in brain / 2297005
Method involves determining adrenal glands cortex hormone cortisol content in blood. At its level below the bottom border of the norm making from 260.0 up to 450.0 nmole/l, within the limits of cortisol concentration fluctuations from 70.0 to 240.0 nmole/l, extracranial metastases development are predicted to occur in 1-3.5 months after primary examination.
Method for predicting physical growth and development of small children / 2291444
Method involves determining triiodothyronine content in peripheral blood serum of children of the second half-year of life having perinatal central nervous system injury manifestations and no signs of hypothyroidism. The value being equal to 0.69±1.34 ng/ml, the children are predicted to have small height to the third year of life.
 Method for carrying out monitoring of diabetes mellitus patients state and neurological and vascular complications development / 2291437
Method involves determining immune reactivity of blood serum with respect to insulin, to anti-insulin antibodies or their antigen-binding fragments, to anti-anti-insulin antibodies binding the antibodies to insulin and antigens to growth factor or their antigen-binding fragments and ANCA antigen. Blood serum immunoreactivity increase with respect to parameters under measurement relative to norm is used for determining diabetes mellitus neurological and vascular complications development.
 Method for predicting the phases of stress states / 2288475
In patient's blood one should detect the concentration of cortisol and fertile factors α2-microglobulin (AMGF), trophoblastic β1-1-glycoproteide (TBG) and α1-placental microglobulin (PAMG-1). The phases of stress states should be diagnosed by the coefficient calculated due to dividing the sum of AMGF and TBG concentrations by the sum of PAMG-1 and cortisol concentrations, moreover, the concentration should be expressed in % against average values in healthy persons. Coefficient's value being equal to 1.0-11 corresponds to the norm; at its value being 1.2-1.5 one should diagnose the phase of anxiety; at 0.7-0.9 - the phase of resistance; at 0.2-0.6 - the phase of exhaustion. The innovation provides the chance to program the flow of pathological process more accurately.
Method for predicting the development of gastrointestinal tract paresis in patients with vertebral traumas / 2286089
In patients with vertebral traumas for about 2-3 h after lesion one should simultaneously determine the level of hormone cortisol, malonic dialdehyde (MDA) in blood serum, and, also, the value of total bioelectric activity (TBEA) of gastrointestinal tract (GIT) and at cortisol values being 981.7 nM/l and higher, and MDA values - 8.35 mM/l and higher and values of TBEA being 387.75 mcV and lower it is possible to predict the development of GIT paresis.
Method for predicting the development of stress reactions in early neonatal period in neonatals born in females with urogenital infection / 2284526
In serum of peripheral blood in pregnant women in trimester III of pregnancy period it is necessary to determine serotonin concentration. The flow of stress reactions in early neonatal period in neonatals should be predicted at serotonin level being above 0.1 mcg/ml. Application of the present method provides the opportunity for earlier prediction of the development of stress reactions in neonatals in early neonatal period.
Method of prognosing generalization of process in children and adolescents with osteal sarcoma / 2282195
Method provides for early prognosis of generalization disease due to most wide biological action of thyroidal hormones regulating principal stages of metabolic processes in body and influencing proliferation velocity and functions of nervous and immune systems, whose status, in turn, greatly determines state of antitumor résistance. Method is characterized by performing complex antitumor treatment and biochemical investigation and in patients undergone complex treatment with complete clinical and laboratory remission level of free fraction of thyroidal hormone triiodothironine is determined in blood. When this level lies within a range of 4.0 to 5.2 pmol/ml, preservation of remission during 6 to 24 month is forecasted and, at the level 5.8 to 7.4 pmol/ml, generalization of malignant process within period of 1 to 3 months is expected.
Method for diagnosing obliterated form of congenital adrenal gland cortex hyperplasia / 2279090
Method involves carrying out test with adrenocorticotropic. Blood levels of 11-desoxycortisol (S), cortisol (F), cortisone (E) and corticosterone (B) are determined by means of high performance liquid chromatography. Ratios of cortisol-to-cortisone levels (F/E) and to 11-desoxycortisol level (F/S) are calculated. Corticosterone level being lower than 17 ng/l and 11-desoxycortisol level being greater than 7.0 ng/l with F/E<5 and F/S<16, obliterated form of congenital adrenal gland cortex hyperplasia is to be diagnosed.
Method for predicting relapses in skin melanoma patients / 2275637
Method involves measuring daily estrone, estradiol and estriol excretion in women of reproductive age. Relation between estriol excretion and total amount of estrone and estradiol excretion after treatment and at control examination stage is calculated. The value being found to grow, relapse is predicted to occur in 11-12 months after the treatment.
Method for differential diagnostics of mammary diseases in men / 2244308
The present innovation deals with biochemical trials: before the onset of therapy in men one should detect blood content of thyroid hormone - free thyroxine - and at its level being 10.3-12.9 pmol/l one should diagnose mammary cancer, at the level of free throxine being 18.7-31.0 pmol/l - one should predict gynecomastia. The method enables to detect the direction of pathological process and carry out due correction of therapy tactics in men with either gynecomastia or mammary cancer.
Method for predicting the delay of intrauterine fetal development / 2246733
The method deals with studying blood serum of pregnant woman to detect the content of insulin-like growth factor (IGF) and vascular-endothelial growth factor (VEGF) and calculate the coefficient of their ratio: at its value being equal to 28.5 and lower it is possible to diagnose the delay of fetal development.
Method for differential diagnostic of chronic hepatitis and hepatic cirrhosis / 2254577
Thyroglobulin content is determined in blood serum using enzyme immunoassay. When thyroglobulin level is increased by 2 times and more compared in contrast with normal one chronic hepatitis is diagnosed, and when thyroglobulin level is decreased by 1.5-2.5 times in contrast with normal one hepatic cirrhosis is diagnosed.
Method for evaluating combined schizophrenia treatment based on atypical antipsychotic drugs and rations and electroconvulsive shock therapy / 2256181
Method involves determining dehydroepiandrosterone sulfate concentration in blood serum. Its growth above 30% when compared to the initial one being observed, treatment efficiency is determined as negative.
Method for diagnosing obliterated forms of congenital suprarenal gland cortex hyperplasia / 2261447
Method involves applying high effectiveness liquid chromatography for determining cortisol, cortisone 11-deoxycorticosterone, 11-deoxycortisone concentration in blood and free cortisol and free cortisone excretion with urine. Ratios of F/E and FF/FE are calculated, where F is the cortisol level in blood; E is the cortisone level in blood; FF is the free cortisol excretion with urine and FE is the free cortisone excretion with urine. The cortisol level in blood not exceeding norm and at least two of three signs: F/E ratio reduction by 25% and more, FF/FE ratio reduction by 25% and more, free cortisol excretion with urine being equal to 25% and more, obliterated forms of congenital suprarenal gland cortex hyperplasia is diagnosed. Corticosterone level in blood growing by 50% and higher, 21-hydroxylase defect is considered to be the case. 11-deoxycorticosterone and/or 11-deoxycortisone concentration in blood being et or greater than 50%, 11β-hydroxylase defect is considered to be the case.
 Method for diagnosing atrophic gastritis cases / 2262706
Method involves making pepsinogen 1, gastrin and Helicopter pylori infection marker combinations analysis and making input of the obtained results into data processing means comprising operation system, means for receiving, transmitting and processing data. The mentioned data processing means is usable for comparing the measured concentration value of a substance under study to a threshold value associated to the substance under study and producing information as a response to comparison results and additionally to other entered data. A set and software are used for implementing the method.
Method for predicting relapse of mammary cancer / 2263319
In the course of surveying in menopausal women after complex therapy one should state the development of mammary cancer at decreased ratio of estriol concentration to the sum of estrone and estradiol urinary concentrations from 1.68±0.23 in relapse-free patients up to 0.74±0.12 - in patients living without relapses for less than a year, up to 0.65±0.13 in patients living without relapse from 2 up to 6 years and up to 0.50±0.10 in patients with relapse-free period from 6 to 10 years. The innovation provides pre-clinical detection of mammary cancer relapse.
Method for predicting fetoplacental insufficiency in pregnant women with thyroid diseases / 2263919
Except detecting placental lactogen in blood serum one should study the content of alphafetoprotein. At placental lactogen content being below 75% against the norm and content of alphafetoprotein below 70% against the norm it is possible to conclude upon availability of fetoplacental insufficiency.
Method for predicting cholecystitis and cholelithiasis / 2263920
While diagnosing cholecystitis and cholelithiasis due to ultrasound testing one should additionally study blood plasma and bile to detect there the content of prostaglandins PGE2 and PGF2α. At PGE2/PGF2α ratio in blood plasma being equal to 6 and more, and, also, at decreased level of biliary cholecystokinin-pancreosimin by 38% and more, biliary PGE2 by 59% and more and increased level of biliary prostaglandin PGF2α by 5.9 times and more against the norm one should diagnose chlecystitis and cholelithiasis. The innovation enables to detect the above-mentioned diseases at earlier stage.
Method for predicting powerless labor in pregnant nodular goiter surgically treated on goiter occasion during pregnancy under medical supervision / 2273456
Method involves determining thyroid gland node diameter and thyrotropic hormone by applying ultrasonic examination approach. Histological examination is carried out with conclusion concerning morphologic nature being obtained like nodular colloid proliferating goiter or thyroid gland adenoma. Diagnostic index Σ is calculated from formula Σ=0.49*K1+0.07*K2-0.5*K3+1.76*K4-1.53, where K1 is the thyroid gland node diameter; K2 is the TTH concentration; K3 is the nodular colloid proliferating goiter index equal to 1 or 0; K4 is the thyroid gland adenoma index equal to 1 or 0. Diagnostic index Σ being less than zero, conclusions concerning powerless labor threat is to be drawn.
|
FIELD: medicine. SUBSTANCE: method involves determining cortisol hormone concentration in cerebral metastasis-ill patient blood prior to treatment beginning. Its concentration being found within the limits of 54.0 to 130.0 nmole/l, metastatic lesion foci are predicted to be available in other internal organs and tissues. EFFECT: high forecasting accuracy and information capacity. 1 tbl
The invention relates to medicine, namely to Oncology, and can be used for the appointment of adequate treatment depending on the presence or absence in patients with metastatic lesions of the brain simultaneously metastases in other organs and tissues. The development of metastatic lesions in the brain in patients after radical treatment of the primary tumor suggests the generalization of the disease and the occurrence of metastases, in addition to the brain, and also in other organs and tissues. The presence or absence of extracranial metastasis in cancer patients with metastatic brain has an important prognostic value for the development in each case adequate treatment plans, timely individualization which, taking into account the prevalence of the disease may lead to a greater effectiveness of therapeutic interventions. The need for information about the status of the metastatic process in the body determines the relevance of search additional, relatively low-cost and quickly implementable laboratory tests, enabling the Clinician to carry out in the group of patients with metastases in the brain primary screening of patients on the prevalence of the disease and involvement in the metastatic process on the natives of organs and tissues. The search for such tests it is advisable to do, in particular, among the compounds secreted by endocrine glands that are relevant to the regulation of protective and adaptive reactions developing in the body under the influence of malignant growth. The adrenal cortex is a Central part of the endocrine system, the functional state of which determines the formation of such reactions and it can change under the influence of various endogenous factors, including tumor development. A known method of differential diagnosis of inflammatory lung diseases and lung cancer (see patent No. 2021758 from 30.10.94, bull. No. 20), the essence of which consists in determining the amount of extravascular fluid in the lungs. Depending on its volume diagnose or lung cancer when the content of extravascular fluid within 49,15-93,35 mg/sqm, or inflammatory process, if its volume varies 129,40-216,60 mg/sq.m. the Proposed method improves the quality of diagnosis. The disadvantage of this method is the need for intravenous administration to the patient of two compounds, radioactive label. In addition, the method is not applicable for the differential diagnosis of inflammatory diseases and cancer at other sites. A known method for the diagnosis of metastases in the liver, in the last of us as a prototype (see patent No. 2027997 from 27.01.95, bull. No. 3). The inventors propose to diagnose the presence of metastases in the liver by determining the activity in the blood of the enzyme gamma-glutamyl transferase after incubation, the serum of patients with homogenate of the liver of intact rats. If after incubation, the enzyme activity increases more than 2 times compared to control, diagnose metastases in the liver. The disadvantage of this method is the ability to determine the presence of metastases confined to the liver, the method cannot be applied for similar purposes in relation to other organs and tissues. The aim of the invention is the detection in cancer patients with metastases in the brain the presence of metastases in other organs and tissues. This goal is achieved by the fact that patients with metastases in the brain before treatment to determine the blood content of the adrenal cortex hormone cortisol and the cortisol levels from 54.0 to 130,0 nmol/l establish the presence of metastases in other organs and tissues, and when the level of cortisol within the physiological norm - 260,0-450,0 nmol/l - establish the absence of metastases in other organs and tissues. The invention "method for the detection of extracranial metastases in cancer patients with metastatic brain" t aetsa new, as it is unknown the level of medicine in the diagnosis of metastasis in cancer patients during the distribution process by biochemical tests. The novelty of the invention lies in the fact that in patients with metastases in the brain before treatment to determine the blood content of the adrenal cortex hormone cortisol and the cortisol levels from 54.0 to 130,0 nmol/l establish the presence of metastases in other organs and tissues, and when the level of cortisol within the physiological norm - 260,0-450,0 nmol/l - establish the absence of metastases in other organs and tissues. The invention involves an inventive step, as an oncologist and neurosurgeon is not obvious from the level of development of medicine in the diagnosis of metastases in advanced malignant process by biochemical tests. The invention is industrially applicable as it can be reproduced in health care, in medical institutions for diagnostic biochemical studies in Oncology, cancer research institutes, oncologic dispensaries. "A method for detection of extracranial metastases in cancer patients with metastatic brain" is as about what atom. The study included 5 patients with metastases in the brain. Before the start of specific treatment in all patients in the blood was determined by the content of the adrenal cortex hormone cortisol. It was found that the content of cortisol in the blood 4 patients with this cancer ranged from 54.0 to 130,0 nmol/l, that is ranged, not reaching the lower border of physiological fluctuations that constitute normal 260-450 nmol/l In one patient the concentration of the hormone were within normal limits and was 400.0Hz in units of nmol/L. data on concentrations of the hormone were analyzed in connection with the fact of presence or absence in patients with extracranial metastases. Found that 4 patients with low levels of cortisol were, along with the brain, and metastases in other organs and tissues. In contrast, the patient with normal physiological levels of the hormone extracranial metastases were absent. This allows you to treat low hormone to 130,0 nmol/l as informative biochemical test, paired with the presence of extracranial metastases. Thus, the obtained data give reason to use the concentration of cortisol in the blood initially examined patients with metastatic brain disease for fast and reliable enough when rining patients with metastases in other organs.
A specific example of the application of the Method of detection of extracranial metastases in cancer patients with metastatic brain". Clinical example No. 1. Patient 3-NV, born in 1953, the case history No. 15697/N. He enrolled in the Department of neurosurgery, RNII 02.04.2004, with a diagnosis of disseminated melanoma skin of the chest wall, pT2N0M1, with metastatic lesions of the soft tissues of the chest wall, steam is nchima both lungs, mediastinal lymph nodes, metastatic lesion of the left parietal and right parietal-occipital areas of the brain, stage IV. Repeated CT-examination of the chest, carried out in the hospital, confirmed the presence of multiple metastases in both lungs from 0.7 to 3 cm in diameter, with no signs of exudative pleurisy. Lesions of other organs were found. Before treatment, the patient study of cortisol in the blood, which was 86,0 nmol/L. Thus, low levels of cortisol combined with the patient not only the brain, but extracranial metastatic lesions. Clinical example No. 2. Sick T-VA S. B., born in 1956, case history No. 565/about He enrolled in the Department of neurosurgery, RNII 6.11.2004 was diagnosed with cancer of the right breast, T2N0M1, the state after the combined treatment, metastatic lesion in the left hemisphere of the cerebellum, stage IV. Further examination in the hospital (ultrasound abdomen, CT of the chest) did not reveal the patient the presence of extracranial metastatic lesions in other organs. Before spetslechenie 28.10.2004, the patient was investigated cortisol in the blood, which amounted to 400.0Hz in units of nmol/L. Content of cortisol, the patient did not differ from n is RMI, component from 260,0 to 450,0 nmol/l, and combined with the absence of extracranial metastatic lesions. 9.11.2004, the patient was made suboccipital lymphadenopathy craniotomy with removal of metastatic tumor of the left hemisphere of the cerebellum. After the operation carried out 3 courses of drug treatment on the method developed by us. Dynamic observation of the patient for 6 months showed no progression of the disease. Thus, normal levels of cortisol in the blood is associated with the absence of metastatic lesions other internal organs. Technical and economic efficiency "method of detection of extracranial metastases in cancer patients with metastatic brain" is that the detection of the presence or absence of extracranial metastasis in cancer patients with metastases in the brain has important prognostic value for the development of timely treatment plans, timely individualization of treatment of such patients, taking into account the prevalence of the disease, which contributes to higher efficiency of therapeutic interventions. Determining the concentration of cortisol in the blood initially examined patients is accurate, informative biochemical test and can be used for fast access is just a reliable, cheap screening of patients with along with metastatic brain metastases and other internal organs. The method of detection of extracranial metastases in cancer patients with metastatic lesions of the brain, including biochemical, characterized in that the patients before treatment to determine the blood content of the adrenal cortex hormone cortisol and its level from 54.0 to 130,0 nmol/l establish the presence of metastases in other organs, and if its content within the physiological norm - 400.0Hz in units of nmol/l - establish the absence of metastases in other organs and tissues.
|
|||||||||||||||||||||||||